74 results about "BALB/c" patented technology

The invention discloses application of piperlongumine in preparation of a medicine for treating virus-induced myocardial fibrosis. According to the application, an in-vivo myocardial fibrosis model is constructed by infecting a BALB / c mouse with a CVB3 virus, and meanwhile, an in-vitro cell model for proliferation and differentiation of primary myocardial fibroblasts is constructed by inducing TGF-beta1. Results prove that when the piperlongumine is applied to the acute stage (1-14 days), the chronic stage (14-28 days) and the whole course (1-28 days) of the viral myocarditis, the myocardial fibrosis of the viral myocarditis can be remarkably improved, the cardiac function is improved, and the curative effect of the piperlongumine applied to the whole course is superior to that of the piperlongumine applied to the acute stage and the chronic stage; the specific mechanism is that Smad2 / 3 and p-38 / YAP pathways jointly play a role in inhibiting myocardial fibrosis.

This invention discloses an antibody that specifically recognizes Toxoplasma gondii surface antigens and its applications. The invention utilizes hybridoma technology to establish a hybridoma cell line by fusing Balb / C mouse spleen cells with SP2 / 0 cells. Monoclonal antibodies were prepared from these cells using in vitro culture and in vivo ascites induction methods, yielding the monoclonal antibody SH12-S7. This invention provides clinical and research institutions with an antibody that specifically recognizes Toxoplasma gondii surface antigens. It can be used for ELISA assays to detect clinical samples, for immunohistochemical assays to diagnose pathological specimens, and provides a convenient research tool for toxoplasmosis research departments. It has broad application value in the diagnosis and detection of definitive host infections and provides technical support for epidemiological investigations and evaluation of control effects of Toxoplasma gondii.

The present application provides a mouse model for studying microsatellite stable and unstable intestinal cancer. Specifically, the present application provides the use of a hybrid mouse in a reagent or kit for preparing a mouse model animal for constructing MSS type intestinal cancer and MSI-H type intestinal cancer, wherein the mouse is a F1 generation of C57BL / 6 x BALB / c. The mouse model of the present application provides the same genetic background for MSS type intestinal cancer cells and MSI-H type intestinal cancer cells, making the research of MSS type intestinal cancer and MSI-H type intestinal cancer more scientific.

The application belongs to the technical field of biology and particularly relates to an African swine fever virus pNP868R protein monoclonal antibody and a preparation method and application thereof. The application takes the pNP868R protein prepared by eukaryotic expression as an antigen, immunizes BALB / c mice, uses hybridoma technology, and obtains a hybridoma cell line capable of stably secreting the anti-African swine fever virus pNP868R protein monoclonal antibody through cell fusion, indirect ELISA method screening, limited dilution method subcloning and hybridoma continuous passage culture. The application also obtains an African swine fever virus pNP868R protein monoclonal antibody. The monoclonal antibody has high affinity with the pNP868R protein and can be applied in Western-Blot experiments, indirect immunofluorescence experiments, immunoprecipitation experiments and the capture of proteins interacting with pNP868R, and can be used for the diagnosis, prevention or treatment of African swine fever.

The application belongs to the technical field of biotechnology, and particularly relates to a human metapneumovirus mouse-adapted strain and application thereof. Compared with wild strains, the strain can exhibit stronger susceptibility to animals, and can cause typical clinical symptoms and even death. For example, after the strain infects BALB / c mice, the disease symptoms are obvious, 83% of the mice have a severe decrease in body weight to below 75% after infection, and have reached the humane killing standard. Four days after the strain infects BALB / c mice, the mortality rate is above 50%. The strain can be used to construct a cell model or an animal model of human metapneumovirus infection or a disease caused by the human metapneumovirus, and is further used to screen drugs for preventing and / or treating human metapneumovirus infection or a disease caused by the human metapneumovirus. In addition, the strain can also be used to prepare drugs for preventing and / or treating human metapneumovirus infection or a disease caused by the human metapneumovirus, and to prepare antibodies or antisera against the human metapneumovirus.

This invention belongs to the field of animal model construction technology, specifically relating to a mouse immunosuppressive model that maintains a long-term immunosuppressive state, its construction method, and its application. This invention establishes a stable immunosuppressive state model with reduced neutrophil count and no significant decrease in erythrocyte count by administering different doses of immunosuppressants (10-50 mg / kg body weight) to Balb / c mice via a combination of "reduced total dose + multiple gavage administration + satellite monitoring." The method for constructing this mouse immunosuppressive model reduces drug usage, controls neutrophil count rebound, establishes a stable model of reduced neutrophil count, and avoids deep bone marrow suppression (i.e., does not cause an uncontrollable decrease in erythrocyte or platelet count), which is beneficial for long-term experimental conduct and drug evaluation.

The invention discloses a plant lactobacillus AR195 strain and application thereof in preparation of a medicine for preventing and / or treating lung cancer, and belongs to the technical field of microorganisms. Through verification, the plant lactobacillus AR195 can inhibit the growth of lung cancer cells, also has certain prevention and treatment effects in a lung cancer mouse model, and can reduce the tumor burden of a BALB / c mouse lung cancer model by reducing MMP9 secretion, so that the plant lactobacillus AR195 can be used for preventing and assisting in treating lung cancer. Meanwhile, the accumulation of the AR195 bacteria in the lung can be improved to the maximum extent through atomization administration, and meanwhile, the adverse side effects of the whole body are reduced. A new drug source is provided for treatment of lung cancer, a novel treatment strategy is provided for treatment of lung cancer by probiotics, and treatment of lung cancer and development of a novel treatment method are facilitated. Meanwhile, the application range of the plant lactobacillus AR195 strain is widened, and a novel treatment strategy is provided for a potential mechanism of treating lung cancer by probiotics.

The present application belongs to the technical field of bioengineering, and particularly relates to a Claudin18.2 gene engineering antibody based on DNA immunization and a preparation method and application thereof. The Claudin18.2 gene engineering antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises any one of the amino acid sequences shown in SEQ ID NO. 15-16; and the light chain variable region comprises the amino acid sequences shown in SEQ ID NO. 19-20. The Claudin18.2 gene engineering antibody is obtained by immunizing Balb / c mice with full-length plasmid DNA and full-length plasmid DNA+extracellular segment polypeptide as immunogens respectively, obtaining plasma cells capable of secreting specific antibodies against Claudin18.2, and then preparing specific mouse-derived gene engineering antibodies through single-cell optical guidance technology and genetic engineering technology. The gene engineering antibodies have high titer and strong specificity, and have specific recognition ability for natural protein Claudin18.2.

The invention discloses a polyclonal antibody of panda Rbp7 protein as well as a preparation method and application thereof, and belongs to the technical field of antibodies. The first to nineteenth amino acid sequences of the panda Rbp7 protein are used as antigen polypeptides, and are specifically shown as SEQ ID No.1. After chemical synthesis or exogenous expression purification, a Balb / C mouse is immunized, and the polyclonal antibody is obtained through repeated immunization, serum titer detection and affinity chromatography purification. The titer of the antibody is not lower than 1 / 128000, the panda Rbp7 recombinant protein can be efficiently and specifically detected through WB and ELISA, the blank of a protein detection tool is filled, and reliable technical support is provided for research on the functional mechanism of the panda Rbp7 protein.

Provided in the present disclosure are a compound for inhibiting the expression of the LPA gene, a pharmaceutical composition and the use thereof, which belong to the technical field of small nucleic acid drug delivery. The oligonucleotide-conjugated compound and the pharmaceutical composition thereof provided in the present disclosure can significantly inhibit the expression of LPA mRNA in animal liver tissues. The oligonucleotide-conjugated compound and the pharmaceutical composition thereof provided in the present disclosure are helpful for relieving, preventing and / or treating diseases or conditions mediated by LPA gene expression dysregulation.AA Relative expression level of LPA mRNA (%)BB Level of LPA mRNA in liver tissues of Balb / c-HDI miceCC s.c. single dose, 1 mg / kg

The invention belongs to the technical field of food microorganisms, and particularly relates to a lactobacillus paracasei BHP06 with an anti-allergic function. The preservation number of the Lactobacillus paracasei BHP06 is GDMCC (China General Microbiological Culture Collection Center) No: 66270, and the preservation number of the Lactobacillus paracasei BHP06 is CGMCC No: 66270. The lactobacillus paracasei strain provided by the invention has good gastrointestinal tract reverse environment resistance and has good survival ability in simulated gastrointestinal fluid; good self-aggregation capability and hyaluronidase inhibition capability are realized. By establishing a degranulation model of RBL-2H3 cells, it is found that the strain can inhibit mast cell degranulation and relieve allergy; by establishing an RAW264.7 cell inflammation model, the strain disclosed by the invention is found to be capable of inhibiting allergic inflammatory reaction; by establishing an OVA (ovalbumin)-induced BALB / c mouse food allergy model, the strain disclosed by the invention is found to be capable of improving the anti-allergy ability of animals and exerting the activity of relieving food allergy.

The invention belongs to the field of animal models, particularly relates to a granulomatous mastitis animal model and a construction method thereof, and aims to solve the problems of low pathological matching degree and poor repeatability of an existing model. The construction method comprises the following steps: selecting an SPF-grade BALB / c female mouse (10 weeks old, 20-22 g), preparing human mammary gland fresh lesion tissue homogenate and lesion origin staphylococcus aureus liquid (1.4 * 10 < 8 >-1.5 * 10 < 8 > CFU / mL), mixing and emulsifying with a Freund's incomplete adjuvant according to a ratio of 1: 1: 1, injecting to the third pair of mammary glands of the mouse, and completing modeling in two weeks. The pathological characteristics of the model are highly matched with human diseases, the success rate is high, the repeatability is strong, and the model can be used for GM pathogenesis research and therapeutic drug screening.

The invention relates to the technical field of biological medicines, and particularly discloses an anti-PRRX2 monoclonal antibody and application thereof in detection of gemcitabine drug resistance of adenocarcinoma. The antibody is prepared through a hybridoma technology, a BALB / c mouse is immunized with a recombinant human PRRX2 protein, and a high-affinity antibody strain is obtained through cell fusion, screening and monocloning. Sequences of light and heavy chain variable regions of the antibody are shown as SEQ ID No: 7 and SEQ ID No: 8, and sequences of a CDR region are shown as SEQ ID No: 1-6. After the antibody is coupled with HRP, the antibody is used for Western Blot to detect PRRX2 expression in a pancreatic ductal adenocarcinoma (PDAC) patient sample, and the result shows that the detection sensitivity to a gemcitabine drug-resistant sample reaches 96.6%, and the specificity is 100%. The antibody disclosed by the invention has high specificity and stability, provides a reliable tool for clinical drug resistance detection, and is beneficial to formulating an individualized treatment strategy.

The invention belongs to the technical field of preparation of antitumor drugs, and particularly relates to an activatable BODIPY photosensitizer and a preparation method and biological application thereof, and a water-soluble photosensitive probe BDP-1 is obtained by modifying a BODIPY structure with a GSH response unit and piperazine salt. The BDP-1 can be activated by GSH (glutathione) overexpressed by tumor cells, and has good biocompatibility and tumor targeting property. By modifying different functional groups, the imaging effect is better, the water solubility is better, the phototoxicity is stronger, and an excellent PDT effect on a tumor-bearing Balb / c mouse model is shown. This is due to the specific enrichment of BDP-1 on tumor sites, and the concentration of the photosensitizer in tumor tissues is improved, so that the photodynamic therapy efficiency is improved.

The invention provides an anti-sT2 monoclonal antibody as well as application and a product thereof, and relates to the technical field of biology. According to the invention, a Balb / C mouse and a New Zealand white rabbit are respectively immunized by using sT2 immunogen expressed and purified by a eukaryotic system, and the anti-sT2 monoclonal antibodies anti-sT2-mab1 and anti-sT2-mab2, which are high in purity, high in sensitivity, high in specificity and capable of recognizing different antigen epitopes, are obtained through multi-step screening by using a mouse hybridoma and rabbit B cell sorting method. Compared with the traditional homologous antibody pairing which is easy to cause signal weakening due to epitope steric hindrance, the anti-sT2-mab1 and anti-sT2-mab2 are combined, so that the species cross reaction can be obviously reduced. The antibody developed by the invention can be used for immunological detection of immunoblotting, immunofluorescence and the like.

The invention provides an anti-medetomidine monoclonal antibody as well as application and a product thereof, and relates to the technical field of biology. Medetomidine is used for immunizing a Balb / c mouse, splenocytes of the mouse are fused with myeloma cells, hybridoma cells with high specificity are obtained through specific high-throughput screening, a large amount of mouse ascites is obtained through culture and re-immunization, and the mouse ascites with high specificity is obtained. And the medetomidine monoclonal antibody with high purity, high sensitivity and high specificity is obtained through multi-step separation and purification, so that a required raw material is provided for developing an immune test strip for detecting medetomidine. The anti-medetomidine monoclonal antibody disclosed by the invention can be used for immunological detection such as immunoblotting and immunofluorescence, and the obtained antibody is proved to have good specific binding capacity.

The invention relates to the technical field of protein detection, and particularly provides a double-antibody sandwich ELISA kit for detecting H5 subtype avian influenza virus M1 protein. The inactivated H5 subtype avian influenza virus subjected to sucrose density gradient centrifugal concentration and purification is used as an immunogen to immunize a BALB / c mouse, the H5 subtype avian influenza virus M1 protein is used for screening to obtain a detection antibody, and the detection antibody is prepared after an SPF chicken is immunized. On the basis, a double-antibody sandwich ELISA kit for detecting the H5 subtype avian influenza virus M1 protein is researched and developed. The technology can be used for quantitative detection of H5 subtype avian influenza M1 protein and quality control of avian influenza subunit products, and ensures stable product quality; and the method can also be used for detecting the expression characteristics of the recombinant avian influenza baculovirus seed protein.

The application provides an anti-glycocholic acid antibody and application thereof, and specifically, the application immunizes BALB / C mice with a glycocholic acid antigen, and more than ten positive monoclonal hybridoma cell strains are screened and obtained. Through performance determination, finally, 3 cell strains capable of specifically combining with glycocholic acid are obtained. Among them, the H15 antibody has high titer, good stability, and stable detection linearity, and can be used for clinical detection of glycocholic acid.

The invention provides an anti-trihexylol monoclonal antibody as well as application and a product thereof, and relates to the technical field of biology. The method comprises the following steps: immunizing a Balb / c mouse by using trihexylamine, fusing splenocytes of the mouse with myeloma cells, carrying out specific high-throughput screening to obtain hybridoma cells with high specificity, and carrying out culture and re-immunization to obtain a large amount of mouse ascites. And the monoclonal antibody resisting the trihexylamine with high purity, high sensitivity and high specificity is obtained through multi-step separation and purification, so that a required raw material is provided for developing an immune test strip for detecting the trihexylamine. Through verification, the monoclonal antibody for resisting the trihexylamine disclosed by the invention has good specific binding capacity.

The invention relates to an anti-OXA-48 carbapenemase monoclonal antibody as well as a preparation method and application thereof. According to the invention, OXA-48 type carbapenemase recombinant protein is taken as an immunogen, BALB / c mice are immunized to prepare the anti-OXA-48 type carbapenemase monoclonal antibody, and gene sequences of a heavy chain variable region and a light chain variable region of the antibody are provided. The monoclonal antibody disclosed by the invention is strong in specificity and high in sensitivity, can be subjected to specific reaction with OXA-48 type carbapenemase, does not react with carbapenemase such as NDM-1, IMP-1, KPC-2, VIM-2 and OXA-23, can be applied to various immunological detection methods, provides a new tool for prevention and detection of OXA-48 type carbapenemase, and has a wide application prospect. The OXA-48 carbapenemase can also be used for developing drugs for preventing and treating diseases caused by OXA-48 carbapenemase infection, and has good application value.

The invention belongs to the technical field of microbial immunity and DNA vaccines, and particularly relates to a preferred epitope peptide of a Crimean-Congo hemorrhagic fever virus envelope glycoprotein C terminal (CCHFV Gc), a tandem multi-epitope vaccine, an expression vector and application. The preferable epitope peptide is composed of any one amino acid sequence as shown in SEQ ID NO.1-SEQ ID NO.21, and the preferable epitope peptide has high affinity, strong immunogenicity and interspecific amp; and an intraspecific conservative preferred epitope. Preferably epitopes are connected in series through a linker to synthesize a series multi-epitope vaccine, the series multi-epitope vaccine enters cells to be expressed to form recombinant protein, then T lymphocytes are activated, and cellular immune response is induced. The in-vivo vaccine evaluation of animals is carried out by using the tandem multi-epitope vaccine, and it is proved that the vaccine can effectively induce anti-CCHFV specific cellular immune response and the application safety in BALB / c mice. The invention is helpful for understanding the immunobiology of CCHFV Gc and perfecting the epitope vaccine design for the virus in the future.

The invention relates to a type II herpes simplex virus strain HSV-2 / KM-1 and application thereof, and belongs to the technical field of virus microorganisms. The II-type herpes simplex virus strain HSV-2 / KM-1 is preserved in the China Center for Type Culture Collection on July 25, 2025, and the preservation number of the II-type herpes simplex virus strain HSV-2 / KM-1 is CCTCC (China Center for Type Culture Collection) NO: V202550. The II-type herpes simplex virus strain HSV-2 / KM-1 disclosed by the invention has cell tropism and tends to infect genital epithelial cells; the II-type herpes simplex virus strain HSV-2 / KM-1 is applied to neutralizing antibody detection of mouse serum, and the instrumental effect of the II-type herpes simplex virus strain HSV-2 / KM-1 in immunogenicity evaluation of vaccines is disclosed. According to the invention, the II-type herpes simplex virus strain HSV-2 / KM-1 is simultaneously utilized to successfully construct a Hartley guinea pig genital herpes model or a BALB / c mouse genital herpes model, and the models can be used as new tools for HSV-2 vaccine evaluation.

The invention belongs to the technical field of biological medicines, and particularly relates to application of parinumod in preparation of a medicine for treating biliary atresia. The invention discovers the treatment application of the S100A8 / A9 inhibitor in biliary atresia for the first time. The method comprises the following steps: inducing the formation of BA by intraperitoneal injection of RRV within 24 hours after a BALB / c newborn mouse is born, and after the RRV is injected from the intraperitoneal cavity, from the second day, injecting an S100A8 / A9 inhibitor Paquinimod (dosage: 50 mg / kg) into the intraperitoneal cavity of the mouse once every other day until the twelfth day. It can be observed that the survival time of the BA mouse treated by Paquinimod is prolonged, the jaundice symptom is relieved, the liver function index is obviously improved, and the infiltration number of inflammatory cells around the hepatic bile duct is obviously reduced. The invention provides a new potential target and a treatment strategy for treatment of BA.

The application provides a kind of low sensitization of penaeus vannamei and its preparation method and application, belong to food biotechnology field.The application uses fucoidan to treat penaeus vannamei by covalent modification, after treatment, protein spatial conformation has changed significantly, allergen epitope is hidden.After BALB / c mouse sensitization model and RBL-2H3 cell degranulation model test shows, the sensitization of covalent modification penaeus vannamei decreases by 72.88%, low sensitization penaeus vannamei can inhibit mast cell degranulation and increase the threshold of sensitization, but still has immunogenicity.Through the construction of BALB / c mouse oral tolerance model, it is found that low sensitization penaeus vannamei can significantly alleviate the multiple immunoglobulin-mediated hypersensitivity caused by mouse allergy, which proves that low sensitization penaeus vannamei has auxiliary effect on oral tolerance, can promote oral tolerance ability, can be used as an effective immune tolerance agent for shrimp allergy patients.

The application discloses a fusion membrane of Staphylococcus epidermidis vesicles and curcumin-derived exosome-like vesicles and a preparation method and application thereof. The application fuses Staphylococcus epidermidis vesicles and curcumin-derived exosome-like vesicles to obtain HMVs, and verifies the antibacterial effect of the HMVs through in-vitro experiments, and then the HMVs are loaded in hyaluronic acid microneedles. The HMVs MNs nano system can be locally administered by pressing on acne lesions, and the in-vivo experiments on Balb / c mice prove that the system has relatively remarkable antibacterial and anti-inflammatory effects. Therefore, the HMVs MNs have relatively good application potential in treating acne.

The invention relates to the technical field of cell culture, in particular to a method for induced culture of embryonic stem cells. The method comprises the following steps: resuscitating cryopreserved Balb / c mouse embryonic stem cells, culturing with a culture solution A containing leukemia inhibition factors, and continuously culturing with a culture solution B containing Activin A after passage; sequentially culturing in an HM culture medium added with specific cell factors, and cooperatively using a cell induction matrix prepared from various components such as hyaluronic acid, 3-aminophenylboronic acid, mono-ammonium glycyrrhizinate and the like. Through the synergistic effect of each culture step and each component in the cell induction matrix, the liver microenvironment is simulated, the cell growth factors are slowly released, and meanwhile, the anti-oxidation characteristic of quercetin is exerted, so that the induced differentiation efficiency of the embryonic stem cells is effectively improved.

The present application relates to the field of biotechnology and in vitro diagnosis, in particular to a monoclonal antibody against eosinophil peroxidase and its application. The antibody of the present application can directly and specifically capture the eosinophil peroxidase with enzymatic activity, and is used in biological research and clinical diagnosis of eosinophils. The monoclonal antibody against eosinophil peroxidase of the present application is prepared by immunizing Balb / c mice with recombinant eosinophil peroxidase as an immunogen, then fusing the spleen with myeloma cells NS1, and screening and purifying. The prepared monoclonal antibody against eosinophil peroxidase specifically recognizes the epitope of eosinophil peroxidase.

The invention provides a method for constructing a myositis-related interstitial lung disease mouse model, which comprises the following steps: injecting 10 micrograms of ODN2395 into the abdominal cavity of a female BALB / c mouse, injecting 0.25 mL of a mixed emulsion of SD (Sprague Dawley) rat skeletal muscle homogenate and a complete Freund's adjuvant into each of the two sides of the back of the female BALB / c mouse at the same time point, and feeding for a certain time to obtain a film-formed mouse. The method has the advantages that raw materials are easy to obtain, and the modeling method is simple; 2, the modeling time is relatively short; and 3, the model forming rate is high, and the method is more in line with the pathogenesis and pathological phenotype of IIM-ILD.